Medical Properties Trust, Inc. MPT
Composite 38/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 18/100 — a strong mark against it.
Income ranks 98/100 — a strong point in its favour. Valuation ranks 69/100 — a moderate point in its favour.
Balance-sheet strength ranks 18/100 — a strong mark against it. Momentum ranks 23/100 — a strong mark against it. Growth ranks 27/100 — a moderate mark against it.
What the company does Medical Properties Trust (MPT) owns 378 net-leased hospital facilities across nine countries with ~38,000 licensed beds, enabling operators to unlock real estate value for facility upgrades and operational investments.
Key financials MPT’s profitability metrics are weak: ROE -2.7%, ROA 2.8%, and ROCE 4.5%. Margins show high gross (96.0%) but negative net (-11.5%), with revenue growth at 12.6% and EPS flat. Leverage is high (Debt/Equity 2.13, Net debt/EBITDA 9.72) and interest coverage is tight at 1.04.
Stock health Technical and quality indicators are mixed: momentum is negative over 3m (-5.39%) and 6m (-5.73%), though 12m is positive (19.25%). Sidera’s overall score is 43.7 (Weak quality, attractively valued), with Valuation at 69.6 and Income at 65.9.
Price vs fair value The stock trades at a **discount of 125.10%** to our fair-value estimate of 10.33 and a **discount of 24.49%** to the analyst 12-month target of 5.71. - High leverage and weak profitability (ROE -2.7%, ROCE 4.5%) limit upside (Sidera). - Negative net margins (-11.5%) and tight interest coverage (1.04) raise risk (Key Financials). - Attractive valuation metrics (P/B 0.64, FCF yield 28.5%) support the discount view (Valuation).
Looking forward Forward P/E of 6.67 suggests deep undervaluation, but weak fundamentals (Altman Z 0.09, Piotroski 6/9) and high payout ratio (1054.6%) raise sustainability concerns. Momentum remains fragile (RSI 42.40).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.